Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

MPLT

MapLight Therapeutics Inc

Oct 31 • 04:00PM ET

16.92

-1.45 -7.89 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-	Insider Own	44.78%	Shs Outstand	41.43M	Perf Week	-
Market Cap	701.00M	Forward P/E	-	EPS next Y	-	Insider Trans	52.59%	Shs Float	22.88M	Perf Month	-
Enterprise Value	955.56M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-7.74%
Book/sh	-5.92	P/C	11.59	EPS next 5Y	-	ROE	-	52W High	20.86 -18.87%	Perf Year	-
Cash/sh	1.46	P/FCF	-	EPS past 3/5Y	-60.77% -	ROIC	-	52W Low	15.00 12.80%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.89	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	4.89	EPS Q/Q	-149.10%	SMA20	-2.68%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	-2.68%	Rel Volume	0.27	Prev Close	18.37
Employees	-	LT Debt/Eq	0.08	Earnings	-	SMA200	-2.68%	Avg Volume	1.20M	Price	16.92
IPO	Oct 27, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	319,985	Change	-7.89%

Oct-29-25 09:06AM	MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-26-25 05:30PM	MapLight Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	Oct 28 '25	Buy	17.00	952,941	16,199,997	3,686,622	Oct 30 04:31 PM
Catalyst4, Inc.	10% Owner	Oct 28 '25	Buy	17.00	5,441,176	92,499,992	19,697,464	Oct 29 04:16 PM

Open in Screener

IOBT

IO Biotech Inc

Oct 31 • 04:00PM ET

1.04

+0.18 20.62 %

Healthcare • Biotechnology • Denmark • NASD

Peers: ARGX FATE TVRD APLS AFMD KURA ANAB ALLK ALXO CTMX

Index	-	P/E	-	EPS (ttm)	-1.58	Insider Own	25.21%	Shs Outstand	65.88M	Perf Week	4.00%
Market Cap	68.52M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	0.09%	Shs Float	49.27M	Perf Month	139.08%
Enterprise Value	48.75M	PEG	-	EPS next Q	-0.32	Inst Own	41.38%	Short Float	2.31%	Perf Quarter	-51.63%
Income	-103.99M	P/S	-	EPS this Y	14.48%	Inst Trans	-2.23%	Short Ratio	0.19	Perf Half Y	1.96%
Sales	0.00M	P/B	43.05	EPS next Y	54.35%	ROA	-135.23%	Short Interest	1.14M	Perf YTD	13.04%
Book/sh	0.02	P/C	2.44	EPS next 5Y	26.32%	ROE	-212.51%	52W High	2.79 -62.72%	Perf Year	-19.69%
Cash/sh	0.43	P/FCF	-	EPS past 3/5Y	17.72% -27.25%	ROIC	-1132.75%	52W Low	0.32 221.58%	Perf 3Y	-58.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.34% 17.45%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-9.69%	Oper. Margin	-	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.96	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.97	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	1.96	EPS Q/Q	-26.75%	SMA20	34.32%	Beta	0.36	Target Price	5.35
Payout	-	Debt/Eq	5.26	Sales Q/Q	-	SMA50	-13.74%	Rel Volume	0.34	Prev Close	0.86
Employees	80	LT Debt/Eq	4.77	Earnings	Aug 14 AMC	SMA200	-15.74%	Avg Volume	6.05M	Price	1.04
IPO	Nov 05, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-12.36% -	Trades		Volume	2,082,704	Change	20.62%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-25	Downgrade	TD Cowen	Buy → Hold
Sep-30-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$0.39

Oct-27-25 08:30AM	Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology (PR Newswire) -9.11%
Oct-20-25 02:30AM	IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 (GlobeNewswire) +25.18%
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire) +6.83%
Oct-01-25 06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)
Sep-29-25 07:05AM	IO Biotech Provides Update Following Pre-BLA Meeting with FDA (GlobeNewswire) -76.89%
08:05AM	Loading…
Sep-23-25 08:05AM	IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025 (GlobeNewswire) +7.38%
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire) -11.54%
Sep-04-25 08:05AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-03-25 12:00PM	IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-26-25 08:39AM	H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14 (Insider Monkey)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-14-25 04:05PM	IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) +68.75%
12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire)
Aug-11-25 01:23PM	IO Biotech to pursue cancer vaccine approval despite Phase III miss (Clinical Trials Arena) -41.99%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:02AM	Loading…
08:02AM	IO Biotech sees path forward for skin cancer vaccine despite study setback (BioPharma Dive)
08:00AM	IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio plus KEYTRUDA (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed (GlobeNewswire)
Aug-10-25 08:00AM	IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma (GlobeNewswire)
May-28-25 09:55AM	IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
May-20-25 08:05AM	IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 12:11PM	IO Biotech price target raised to $14 from $12 at H.C. Wainwright (TipRanks)
May-14-25 08:05AM	IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Apr-26-25 03:05PM	IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-25-25 01:00PM	IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 (GlobeNewswire)
Mar-25-25 04:35PM	IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.00%
Mar-18-25 08:00AM	IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 (GlobeNewswire)
Mar-04-25 04:17PM	IO Biotech Reports 2024 Business Highlights (GlobeNewswire) +5.91%
Feb-23-25 12:07PM	IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference (GlobeNewswire)
Feb-20-25 08:05AM	IO Biotech to Present at the 45th Annual Cowen Health Care Conference (GlobeNewswire) +11.00%
Feb-04-25 08:05AM	IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate (GlobeNewswire) +6.74%
11:10AM	Loading…
Jan-10-25 11:10AM	IO Biotech enrols all subjects in Phase II trial of cancer combination therapy (Clinical Trials Arena)
Jan-09-25 08:05AM	IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer (GlobeNewswire)
Dec-20-24 08:05AM	IO Biotech secures up to 57.5 million in debt financing from the European Investment Bank (GlobeNewswire)
Nov-12-24 07:05AM	IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -11.68%
Nov-11-24 04:05PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 10:00AM	IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study (GlobeNewswire) +6.03%
Oct-04-24 09:00AM	IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +13.86%
Sep-14-24 02:30AM	IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer (GlobeNewswire)
Sep-02-24 06:53AM	IO Biotechs melanoma treatment trial to continue after IDMC review (Clinical Trials Arena)
Aug-30-24 04:05PM	IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma (GlobeNewswire) -33.33%
Aug-26-24 04:05PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 07:05AM	IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +17.69%
Jul-25-24 04:05PM	IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 (GlobeNewswire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
May-23-24 08:30AM	IO Biotech to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 01:54PM	IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024 (InvestorPlace)
07:55AM	IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-24-24 04:30PM	IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-15-24 08:30AM	IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness (GlobeNewswire)
Apr-09-24 12:00PM	IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 (GlobeNewswire)
Apr-05-24 08:30AM	IO Biotech Appoints Faical Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
08:30AM	IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
Mar-07-24 02:01PM	IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com) +6.63%
Mar-06-24 04:11PM	IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-05-24 10:52PM	IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023 (InvestorPlace)
04:40PM	IO Biotech Announces 2023 Fourth-Quarter and Year-End Results (GlobeNewswire)
Feb-26-24 04:05PM	IO Biotech to Present at 44th Annual Cowen Health Care Conference (GlobeNewswire)
Dec-21-23 08:30AM	IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial (GlobeNewswire)
Nov-13-23 08:12AM	IO Biotech Announces 2023 Third Quarter Results (GlobeNewswire)
08:00AM	IO Biotech Appoints Helen Collins, MD, to its Board of Directors (GlobeNewswire)
Nov-10-23 08:00AM	IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma (GlobeNewswire)
Nov-08-23 04:30PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-23 08:30AM	IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +8.38%
Oct-23-23 01:00AM	Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress (GlobeNewswire) -5.05%
Oct-03-23 04:30PM	IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +10.22%
Sep-12-23 08:05AM	IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer (GlobeNewswire) -13.20%
Sep-06-23 08:35AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 08:59AM	10 Best New Penny Stocks to Buy Now (Insider Monkey)
Aug-16-23 09:01PM	Stonepine Capital Management, LLC Acquires New Stake in IO Biotech Inc (GuruFocus.com)
Aug-11-23 08:30AM	IO Biotech Announces 2023 Second Quarter Results (GlobeNewswire)
08:05AM	IO Biotech Appoints Heidi Hunter to its Board of Directors (GlobeNewswire)
Aug-08-23 08:05AM	IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
Aug-07-23 08:30AM	IO Biotech, Inc. Announces $75 Million Private Placement Financing (GlobeNewswire)
Jul-28-23 08:05AM	IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center (GlobeNewswire)
Jul-25-23 04:05PM	IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer (GlobeNewswire)
Jul-18-23 04:05PM	IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer (GlobeNewswire)
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +27.33%
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-14-23 12:42PM	Why Are IO Biotech Shares Trading Lower Today (Benzinga) -26.48%
08:00AM	IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone (GlobeNewswire)
Jun-01-23 08:30AM	IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead (GlobeNewswire)
May-30-23 04:35PM	IO Biotech to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:05PM	IO Biotech Announces 2023 First-Quarter Results (GlobeNewswire) +9.69% -7.91%
May-02-23 07:22AM	Is IO Biotech (NASDAQ:IOBT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-22-23 06:14AM	The Chief Financial Officer of IO Biotech, Inc. (NASDAQ:IOBT), Amy Sullivan, Just Bought A Few More Shares (Simply Wall St.)
Mar-14-23 04:11PM	IO Biotech Announces 2022 Fourth-Quarter and Year-End Results (GlobeNewswire) -7.79%
Feb-22-23 07:00AM	IO Biotech to Participate in March 2023 Investor Conferences (GlobeNewswire)
Jan-23-23 08:00AM	IO Biotech Announces Appointment of Devin Smith as General Counsel (GlobeNewswire)
Jan-09-23 07:05AM	IO Biotech Provides Business Update (GlobeNewswire)
Nov-21-22 01:23PM	Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated' (Benzinga) -12.11%
Nov-09-22 04:07PM	IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire) +16.73%
04:05PM	IO Biotech Announces Third Quarter Results for 2022 (GlobeNewswire)
Nov-03-22 08:00AM	IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors (GlobeNewswire)
Oct-31-22 08:00AM	IO Biotech to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-15-22 08:37AM	Is IO Biotech (NASDAQ:IOBT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-13-22 04:05PM	IO Biotech Announces Appointment of New Chief Financial Officer (GlobeNewswire)
Oct-05-22 08:05AM	IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire) -6.98%
Sep-06-22 07:30AM	IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-11-22 05:00PM	IO Biotech Announces Second Quarter Results for 2022 (GlobeNewswire)

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hunter Heidi	Director	May 30 '25	Buy	1.39	15,000	20,884	15,000	Jun 02 07:53 AM
Ahmad Qasim Iftikhar	Chief Medical Officer	Dec 23 '24	Buy	0.85	31,350	26,553	31,350	Dec 26 08:50 AM
Zocca Mai-Britt	Chief Executive Officer	Dec 23 '24	Buy	0.81	12,500	10,120	49,891	Dec 23 06:56 PM
Sullivan Amy	Chief Financial Officer	Dec 23 '24	Buy	0.83	10,250	8,483	84,632	Dec 23 06:53 PM
Smith Devin Whittemore	General Counsel	Dec 23 '24	Buy	0.81	12,000	9,720	16,938	Dec 23 06:52 PM

Open in Screener

SPRB

Spruce Biosciences Inc

Oct 31 • 04:00PM ET

110.10

+2.85 2.66 %

Healthcare • Biotechnology • USA • NASD

SPRB Spruce Biosciences Inc daily Stock Chart

Index	-	P/E	-	EPS (ttm)	-85.92	Insider Own	17.68%	Shs Outstand	0.56M	Perf Week	-17.37%
Market Cap	117.33M	Forward P/E	-	EPS next Y	-30.38	Insider Trans	-0.00%	Shs Float	0.46M	Perf Month	1180.23%
Enterprise Value	102.76M	PEG	-	EPS next Q	-13.94	Inst Own	61.69%	Short Float	4.46%	Perf Quarter	1123.33%
Income	-48.34M	P/S	90.25	EPS this Y	87.09%	Inst Trans	-26.67%	Short Ratio	0.04	Perf Half Y	1887.81%
Sales	1.30M	P/B	4.70	EPS next Y	-143.23%	ROA	-99.32%	Short Interest	0.02M	Perf YTD	249.52%
Book/sh	23.41	P/C	7.16	EPS next 5Y	26.41%	ROE	-133.62%	52W High	240.00 -54.13%	Perf Year	148.86%
Cash/sh	15.38	P/FCF	-	EPS past 3/5Y	10.79% -16.93%	ROIC	-351.29%	52W Low	4.28 2475.44%	Perf 3Y	26.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	97.54%	Volatility	14.39% 37.39%	Perf 5Y	-92.37%
Dividend TTM	-	EV/Sales	79.05	EPS Y/Y TTM	-8.91%	Oper. Margin	-3900.38%	ATR (14)	18.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.60	Sales Y/Y TTM	-86.43%	Profit Margin	-3721.17%	RSI (14)	50.98	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.60	EPS Q/Q	79.10%	SMA20	-23.96%	Beta	3.08	Target Price	207.00
Payout	-	Debt/Eq	0.14	Sales Q/Q	-100.00%	SMA50	74.41%	Rel Volume	0.46	Prev Close	107.25
Employees	21	LT Debt/Eq	0.04	Earnings	Aug 14 AMC	SMA200	308.82%	Avg Volume	479.81K	Price	110.10
IPO	Oct 09, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	80.56% -	Trades		Volume	220,099	Change	2.66%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-28-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$254

Oct-15-25 12:00PM	What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? (Zacks) -10.09%
Oct-08-25 08:00AM	Spruce Biosciences Announces $50.0 Million Private Placement Financing (Business Wire) -12.34%
Oct-07-25 09:44AM	This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. (Barrons.com) +40.03%
Oct-06-25 05:04PM	Why Spruce Biosciences Just Skyrocketed Almost 1,400% (Investor's Business Daily) +1,378.46%
08:00AM	Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire)
07:00AM	Loading…
Sep-15-25 07:00AM	Spruce Biosciences Resumes Trading on the Nasdaq Capital Market (Business Wire) -20.97%

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gharib Samir M.	PRESIDENT AND CFO	Oct 20 '25	Option Exercise	0.00	2,053	0	6,727	Oct 22 04:15 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Oct 20 '25	Option Exercise	0.00	4,784	0	11,013	Oct 22 04:15 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Buy	17.91	256	4,585	1,307	Oct 15 04:32 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Sale	19.14	257	4,920	1,050	Oct 15 04:32 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Buy	17.91	256	4,585	1,307	Oct 08 08:55 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Sale	19.14	257	4,920	1,050	Oct 08 08:55 PM

Open in Screener

MGX

Metagenomi Inc

Oct 31 • 04:00PM ET

2.54

+0.10 4.10 %

Healthcare • Biotechnology • USA • NASD

Peers: NTLA CRSP EDIT BEAM VERV PRME DNLI VRTX SGMO ARCT

| Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-2.35	Insider Own	29.77%	Shs Outstand	37.53M	Perf Week	-12.11%
Market Cap	95.33M	Forward P/E	-	EPS next Y	-2.23	Insider Trans	-0.22%	Shs Float	26.36M	Perf Month	2.01%
Enterprise Value	-66.67M	PEG	-	EPS next Q	-0.58	Inst Own	19.80%	Short Float	6.11%	Perf Quarter	10.43%
Income	-87.12M	P/S	2.82	EPS this Y	-1.47%	Inst Trans	-10.67%	Short Ratio	2.69	Perf Half Y	57.76%
Sales	33.77M	P/B	0.49	EPS next Y	6.95%	ROA	-26.47%	Short Interest	1.61M	Perf YTD	-29.64%
Book/sh	5.22	P/C	0.47	EPS next 5Y	-13.99%	ROE	-37.45%	52W High	4.92 -48.37%	Perf Year	27.64%
Cash/sh	5.46	P/FCF	-	EPS past 3/5Y	-53.91% -	ROIC	-37.34%	52W Low	1.23 106.50%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	499.26% -	Gross Margin	83.66%	Volatility	8.85% 10.68%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-1.97	EPS Y/Y TTM	6.83%	Oper. Margin	-271.89%	ATR (14)	0.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.36	Sales Y/Y TTM	-39.62%	Profit Margin	-257.99%	RSI (14)	46.68	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	6.36	EPS Q/Q	-86.89%	SMA20	-12.16%	Beta	0.30	Target Price	10.00
Payout	-	Debt/Eq	0.22	Sales Q/Q	-57.45%	SMA50	6.98%	Rel Volume	0.43	Prev Close	2.44
Employees	202	LT Debt/Eq	0.19	Earnings	Aug 12 AMC	SMA200	25.03%	Avg Volume	598.53K	Price	2.54
IPO	Feb 09, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	12.76% 0.69%	Trades		Volume	258,347	Change	4.10%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Initiated	H.C. Wainwright	Buy	$10
May-02-24	Downgrade	JP Morgan	Overweight → Neutral	$16 → $6
Mar-05-24	Initiated	Wells Fargo	Overweight	$25
Mar-05-24	Initiated	TD Cowen	Outperform
Mar-05-24	Initiated	JP Morgan	Overweight	$16
Mar-05-24	Initiated	Jefferies	Buy	$23
Mar-05-24	Initiated	Chardan Capital Markets	Buy	$21
Mar-05-24	Initiated	BMO Capital Markets	Outperform	$22

Oct-22-25 10:02AM	Metagenomi taps Amazon's custom chips to develop gene-editing tools (Reuters) -8.57%
Oct-20-25 12:00PM	Here's Why Metagenomi (MGX) is a Great Momentum Stock to Buy (Zacks) +9.84%
Aug-12-25 05:40PM	Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:25PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:37PM	Metagenomi: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-11-25 04:05PM	Metagenomi Appoints Laurence Reid, PhD to its Board of Directors (GlobeNewswire)
Aug-07-25 08:35AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.57%
Jul-29-25 10:23AM	Metagenomi (MGX) Presents Latest in Gene Editing Technologies (Insider Monkey) -6.56%
Jul-18-25 10:06AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains? (Zacks) -6.57%
09:41AM	Oracle's AI-driven surge: Can its stock rally last? (Yahoo Finance)
Jul-14-25 11:12AM	Metagenomi Showcases Advanced AI-Enhanced Gene Editing for Neurological Disorders at ASGCT Meeting (Insider Monkey)
May-14-25 06:00AM	Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025 (GlobeNewswire) -6.25%
May-13-25 05:40PM	Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:42PM	Metagenomi: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	Loading…
04:30PM	Metagenomi Reports Business Updates and First Quarter 2025 Financial Results (GlobeNewswire)
May-08-25 09:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +9.66%
May-06-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.96%
May-02-25 07:00AM	Metagenomi to Present at Upcoming Scientific Meetings (GlobeNewswire) +8.05%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-17-25 04:05PM	Metagenomi Reports Business Updates and Full Year 2024 Financial Results (GlobeNewswire) -7.98%
Mar-13-25 06:19AM	Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems (GlobeNewswire) -6.83%
Feb-11-25 08:55AM	Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference (GlobeNewswire) -6.17%
Jan-28-25 08:00AM	Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer (GlobeNewswire)
Jan-22-25 11:54AM	People are buying the wrong stock thinking it's part of OpenAI's Stargate Project (Quartz) +11.40%
Jan-16-25 08:55AM	Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones (GlobeNewswire)
Jan-15-25 08:55AM	Metagenomi Announces New Appointment to its Board of Directors (GlobeNewswire)
Jan-08-25 04:05PM	Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.36%
Dec-11-24 06:30PM	Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference RNA at the Bench and Bedside IV (GlobeNewswire) -5.73%
Dec-09-24 09:16PM	Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting (GlobeNewswire) +125.41%
06:05AM	Loading…
Dec-08-24 06:05AM	Jefferies Predicts Up to ~1000% Surge for These 2 Strong Buy Stocks (TipRanks)
Nov-18-24 12:00PM	What Makes Metagenomi (MGX) a New Buy Stock (Zacks)
Nov-13-24 04:37PM	Metagenomi: Q3 Earnings Snapshot (Associated Press Finance) -10.90%
04:05PM	Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 04:05PM	Metagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting (GlobeNewswire)
Oct-29-24 05:45AM	Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Oct-24-24 08:04AM	Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT (GlobeNewswire)
Oct-23-24 05:45AM	Investors in Metagenomi, Inc. Should Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Oct-14-24 08:58PM	Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies (GlobeNewswire)
Oct-01-24 03:14PM	Metagenomi, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Sep-19-24 07:15PM	Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -6.84%
Sep-03-24 04:05PM	Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months (GlobeNewswire)
Aug-29-24 07:32PM	Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference (GlobeNewswire)
Aug-28-24 06:10PM	Metagenomi to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
Aug-26-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Metagenomi, Target Hospitality, Helios, and LegalZoom and Encourages Investors to Contact the Firm (GlobeNewswire)
Aug-14-24 08:11AM	Metagenomi: Q2 Earnings Snapshot (Associated Press Finance)
08:05AM	Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 06:29PM	Metagenomi, Inc. (MGX): This New Penny Stock Received a Positive Rating From Street Analysts (Insider Monkey) +10.54%
Aug-05-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Dril-Quip, LPL Financial, Methode, and Metagenomi and Encourages Investors to Contact the Firm (GlobeNewswire)
Jun-03-24 04:30PM	Is Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now? (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-29-24 04:00PM	Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 10:54PM	MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results (GlobeNewswire)
May-04-24 10:49AM	Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) -12.36%
May-01-24 04:00PM	Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems (GlobeNewswire)
01:53PM	Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight (FierceBiotech.com)
Apr-08-24 08:00AM	Metagenomi to Present at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 09:16AM	Metagenomi Reports Business Updates and Full Year 2023 Financial Results (GlobeNewswire)
Feb-29-24 04:30PM	Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-13-24 04:35PM	Metagenomi Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-08-24 10:16PM	Metagenomi Announces Pricing of Initial Public Offering (GlobeNewswire)

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Noonberg Sarah B.	FORMER OFFICER	Sep 11 '25	Proposed Sale	1.90	35,832	68,081		Sep 11 04:25 PM
Sebastian Bernales	Affiliate	Jul 09 '25	Proposed Sale	1.91	769,845	1,470,404		Jul 09 06:34 PM
Wein Matthew	See Remarks	Jun 06 '25	Sale	1.75	199	348	16,693	Jun 09 07:04 PM
Noonberg Sarah B.	Chief Medical Officer	Jun 06 '25	Sale	1.75	5,239	9,168	109,135	Jun 09 06:57 PM
Wapnick Pamela	Chief Financial Officer	Jun 06 '25	Sale	1.75	1,576	2,758	72,108	Jun 09 06:54 PM
Thomas Brian C.	Chief Executive Officer	Jun 06 '25	Sale	1.75	10,785	18,874	2,517,491	Jun 09 06:50 PM
Irish Jian	See Remarks	Jun 06 '25	Sale	1.75	6,390	11,182	315,543	Jun 09 06:20 PM
Wein Matthew	See Remarks	Mar 05 '25	Sale	1.87	930	1,744	9,467	Mar 07 04:38 PM
Wapnick Pamela	Chief Financial Officer	Mar 05 '25	Sale	1.87	1,808	3,390	59,684	Mar 07 04:36 PM
Wapnick Pamela	Chief Financial Officer	Dec 05 '24	Sale	1.86	1,559	2,900	61,492	Dec 06 04:24 PM

MPLT

MapLight Therapeutics Inc

IOBT

IO Biotech Inc

SPRB

Spruce Biosciences Inc

MGX

Metagenomi Inc

Upgrade your FINVIZ experience